Linked Data API

Show Search Form

Search Results

1137390
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16997 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16998 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.303Zmore like thismore than 2019-07-15T10:23:54.303Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1137391
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16998 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16999 more like this
star this property question first answered
less than 2019-07-15T10:23:54.243Zmore like thismore than 2019-07-15T10:23:54.243Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1137392
star this property registered interest false more like this
star this property date less than 2019-07-08more like thismore than 2019-07-08
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible. more like this
star this property tabling member printed
Baroness Morgan of Huyton more like this
star this property uin HL16999 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16997 more like this
HL16998 more like this
star this property question first answered
less than 2019-07-15T10:23:54.35Zmore like thismore than 2019-07-15T10:23:54.35Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
2168
unstar this property label Biography information for Baroness Morgan of Huyton more like this
1132403
star this property registered interest false more like this
star this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Orkambi remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265417 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-20more like thismore than 2019-06-20
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 265418 more like this
star this property question first answered
less than 2019-06-20T09:33:36.433Zmore like thismore than 2019-06-20T09:33:36.433Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this